ELMDMEDIUM SIGNALOPERATIONAL10-K

ELMD shifted from claiming market-leading product specifications to more modest competitive positioning while delivering solid financial performance.

The company removed superlative claims about having the "smallest, lightest" generator and "lightest HFCWO garment available," suggesting either competitive pressure or regulatory/legal considerations around marketing claims. However, this messaging shift coincided with strong operational execution and profitable growth, indicating the business fundamentals remain healthy despite more conservative product positioning.

Comparing 2025-08-26 vs 2024-08-27View on EDGAR →
FINANCIAL ANALYSIS

ELMD delivered broad-based financial improvement with revenue growing 13.8% to $54.7M and gross profit expanding 19.8% to $50.0M, demonstrating healthy margin expansion. Operating income and net income both grew meaningfully, supported by strong 25.7% growth in operating cash flow to $11.4M. The company increased R&D investment substantially while maintaining disciplined SG&A growth, though total liabilities rose 37.8% and share count declined to 8.3M from 8.6M shares outstanding.

FINANCIAL STATEMENT CHANGES
R&D Expense
P&L
+51.8%
$656K→$996K

R&D investment increased 51.8% — signals commitment to future product development, though near-term margin impact.

Operating Income
P&L
+46.8%
$6.6M→$9.7M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+46.3%
$5.2M→$7.5M

Net income grew 46.3% — bottom-line growth signals improving overall business health.

Total Liabilities
Balance Sheet
+37.8%
$7.7M→$10.6M

Liabilities grew 37.8% — significant increase in debt or obligations, assess impact on financial flexibility.

Current Liabilities
Balance Sheet
+36.4%
$7.7M→$10.5M

Current liabilities surged 36.4% — significant near-term obligations; verify ability to meet short-term debt.

Operating Cash Flow
Cash Flow
+25.7%
$9.1M→$11.4M

Operating cash flow grew 25.7% — strong conversion of earnings to cash, healthy business fundamentals.

Gross Profit
P&L
+19.8%
$41.7M→$50.0M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

SG&A Expense
P&L
+14%
$34.5M→$39.3M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

Revenue
P&L
+13.8%
$48.1M→$54.7M

Revenue growing 13.8% — solid top-line momentum, watch margins for quality of growth.

Inventory
Balance Sheet
-11.1%
$3.7M→$3.3M

Inventory reduced 11.1% — lean inventory management or demand outpacing supply.

LANGUAGE CHANGES
NEW — 2025-08-26
PRIOR — 2024-08-27
ADDED
There were 8,349,176 shares of the registrant s common stock outstanding as of August 20, 2025.
The SmartVest Clearway was designed with patient experience in mind, continuing our history of offering a sleek and light weight generator featuring an intuitive touch screen to simplify use.
Soft-fabric garment is lightweight and comfortable: The SmartVest garment is lightweight and is designed to resemble an article of clothing.
Small and light: SmartVest Clearway is a sleek and lightweight generator, weighing less than 14 pounds.
homecare market for HFCWO was approximately $245 million in calendar year 2024, growing at an 8% compound annual growth rate based on independent third-party market research 2 .
We believe that bronchiectasis is under-diagnosed but is experiencing a surge in clinical interest and awareness, including the relationship to COPD, commonly referred to as bronchiectasis COPD overlap syndrome 3-9 .
The overlap of bronchiectasis and COPD increases exacerbations and hospitalizations, reduces pulmonary function, and increases mortality 10 .
Internal company estimates derived from a 2024 analysis of claims data indicate a 16% penetration of HFCWO within the 923,000 Americans diagnosed with bronchiectasis 18 (see Figure 1 below).
BE Diagnosed Diagnosed BE population growing at ~12% annually Estimated bronchiectasis prevalence, UNDIAGNOSED with COPD/BE overlap 4.1 million U.S.
Undiagnosed 35% of BE patients managed by pulmonologists The heightened awareness of bronchiectasis speaks to the growing body of clinical evidence supporting treatments to improve symptoms and manage disease progression.
REMOVED
There were 8,638,917 shares of the registrant s common stock outstanding as of August 20, 2024.
1 Our Products Since 2000, we have marketed the SmartVest System and its predecessor products to patients suffering from bronchiectasis, cystic fibrosis, and neuromuscular conditions such as cerebral palsy and amyotrophic lateral sclerosis ( ALS ).
The SmartVest Clearway was designed with patient experience in mind, continuing our history of offering the smallest, lightest weight generator on the market and featuring an intuitive touch screen to simplify use.
Soft-fabric garment is lightweight and comfortable: The SmartVest garment is the lightest HFCWO garment available and is designed to resemble an article of clothing.
2 Smaller and lighter: SmartVest Clearway is the smallest and lightest HFCWO generator on the market, weighing less than 14 pounds.
Other Products We market the Single Patient Use ( SPU ) SmartVest and SmartVest Wrap to health care providers in the acute care setting.
market for HFCWO was approximately $235 million in 2023 growing at an 8% compound annual growth rate based on independent third-party market research 15 .
We believe that bronchiectasis is underrecognized and under-diagnosed but is experiencing a surge in clinical interest and awareness, including the relationship to COPD, commonly referred to as bronchiectasis COPD overlap syndrome.
The overlap of bronchiectasis and COPD increases exacerbations and hospitalizations, reduces pulmonary function, and increases mortality.
Several recent studies have estimated prevalence of bronchiectasis, which we believe are helpful for estimating a range of the overall market size.
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →